Taselisib Phosphoinositide 3-kinase inhibitor



Trial Studied treatment Control Patients Size Study type Results NCT

Advanced breast cancer (metastatic) - Phosphoinositide 3-kinase inhibitor in all type of patients

SANDPIPER, 2018taselisib + fulvestrantfulvestrant alone2L ER PIK3CA-MUT516 (340/176) NCT02340221



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons